Drug interactions

Introduction to Pharmacotherapy:
Drug interactions
BY
Getu Bayisa
Assistant Professor of Clinical
Pharmacy, B.Pharm.
RVU|Hachalu Hundessa Campus,
Pharmacy Department
1
Introduction
• A drug interaction results when the effects of a drug
are altered in some way by the presence of another
drug, by food, or by environmental exposure.
• The frequency and significance of drug interactions

vary considerably among different patient
populations.
• Drug interactions are regarded as clinically

meaningful when they have the potential to produce
excessive toxicity or reduce therapeutic activity.
2
Introduction#2
• Some interactions can be exploited for their potential
clinical benefit. E.g., The protease inhibitor ritonavir
• Geriatric patients, polypharmacy and taking drugs

with narrow therapeutics window are risk factors for
drug interactions.
• The clinical severity of the effect of interaction can be

classified as minor, moderate, and
severe(micromedex health series) or as
A,B,C,D,X(lexi-comp).
3
Introduction#3
 Minor drug interactions usually have limited clinical
consequences and require no change in therapy.
 Moderate interactions often require an alteration in

dosage or increased monitoring.
 Severe interactions should generally be avoided

whenever possible, as they result in potentially serious
toxicity.
4
MECHANISMS OF DRUG INTERACTIONS
 A pharmacodynamic interaction results when a drug
interferes with a second drug at its target site, or
changes in some way its anticipated pharmacologic
response.
• Pharmacodynamic interactions do not involve changes
in the concentration of drug in plasma.
 Antagonist
• Drugs with opposing pharmacological actions acting
on the same receptor. E.g., salbutamol (a beta-2
agonist) with metoprolol (a beta-2 antagonist)
5
MECHANISMS OF PD DRUG
INTERACTIONS#2
 Additive:1+1=2
 Drugs with a similar mechanism of action may have
an additive effect. E.g., Fluoxetine (an SSRI) with
clomipramine (a tricyclic antidepressant with
serotonergic activity) can cause serotonin syndrome
in some patients.
 Synergistic:1+1>2
 E.g., Using a combination of antibiotics in treatment
of resistant pathogen.
6
MECHANISMS OF PD DRUG
INTERACTIONS#3
 Fluid/electrolyte imbalance :
E.g., diuretics that cause hypokalaemia can increase
the toxicity of digoxin.
 Indirect interactions:
NSAID’s can reduce the effectiveness of
antihypertensive by causing salt and water
retention.
7
PK interactions
Interactions affecting drug absorption
• Interactions affecting drug absorption may result in
changes in the rate of absorption, the extent of
absorption, or a combination of both
• Interactions resulting in a reduced rate of absorption
are not typically clinically important for maintenance
medications
• For acutely administered medications, such as
sedative-hypnotics or analgesics, a reduction in the
rate of absorption may cause an unacceptable delay
in the onset of the drug’s pharmacologic effect.
8
Interactions affecting drug absorption#2
 A change in the extent of drug absorption that

exceeds 20% is generally considered to be
clinically significant
 The extent of absorption can be affected by

changes in gastrointestinal motility,
gastrointestinal pH, intestinal cytochrome P450
(CYP) enzyme and transport protein activity,
and drug chelation in the gut.
9
Interactions affecting drug absorption#3
 Change in gastrointestinal PH (ketoconazole and H2

- antagonists
 Chelation in the gut (calcium and TTC)
 Change in gastrointestinal motility (Metoclopramide

increases gut motility and prevents complete
absorption of slow dissolving digoxin preparations )
 Change in gastrointestinal flora: digoxin/macrolide,
antibiotics and Oral contraceptives
10
Interactions affecting drug distribution
 Theoretically, drugs that are highly protein bound

(>90%) may displace other highly protein-bound
drugs from binding sites, thereby increasing drug
distribution.
 The transient increase in unbound concentration may
be clinically important for drugs with a limited
distribution, a narrow therapeutic index, or a long
elimination half-life
11
Interactions affecting drug distribution#2
 No examples of clinically significant plasma
protein displacement interactions involving
nonrestrictively metabolized drugs have been
identified
 In general, due to a compensatory increase in

elimination, protein binding displacement
interactions are not usually significant and other
mechanisms are responsible
12
Examples
• Sucralfate, some milk  Block absorption
products, antacids, and of quinolones, tetracycline,
oral iron preparations and azithromycin
• Omeprazole, lansoprazole,  Reduce absorption
H2-antagonists of ketoconazole,
delavirdine
• Didanosine (given
as a buffered tablet)  Reduces ketoconazole
absorption
• Cholestyramine
 Binds raloxifene,
thyroid hormone, and
digoxin
13
Interactions affecting drug metabolism
 Consequences of drug metabolism
 Inactive products
 Active metabolites
 Similar to parent drug
 More active than parent
 New action
 Toxic metabolites
14
Phases of Drug metabolism
15
Interactions affecting drug metabolism#3
 drug metabolism is composed of 2 distinct pathways

of biochemical processing, Phase I and Phase II.
 Phase I: is a chemical modification (typically
oxidation, hydrolysis, or reduction reactions)
performed primarily by members of the CYP enzyme
family
 Phase II metabolism consists of the
biotransformation of endogenous compounds by
reactions such as glucuronidation, sulfation,
methylation, acetylation, and glycine conjugation.
16
 Modulation of CYP-mediated metabolism is the

primary mechanism by which one drug interacts
with another
 Most clinically significant metabolic interactions

involve either inhibition or induction of
cytochrome P-450 enzymes in the liver .
17
Cytochrome P450 Isoforms
 CYP1A2
 CYP3A
 CYP2C9
 CYP2C19
 CYP2D6
18
 An inducer is a drug that causes increased activity
of a CYP isoenzyme by causing increased
synthesis.
 Enzyme inhibition occurs when the inhibitor drug

binds to the CYP isoenzyme and prevents binding
(and therefore metabolism) of the substrate drug.
19
Cytochrome P450 3A
• Responsible for metabolism of:
– Most calcium channel blockers
– Most benzodiazepines
– Most HIV protease inhibitors
– Most HMG-CoA-reductase inhibitors
– Cyclosporine
– Most non-sedating antihistamines
– Cisapride
• Present in GI tract and liver
20
CYP3A Inhibitors
• Ketoconazole
• Itraconazole
• Fluconazole
• Cimetidine
• Clarithromycin
• Erythromycin
• Grapefruit juice
21
CYP3A Inducers
 Carbamazepine
 Rifampin
 Rifabutin
 Ritonavir
 St. John’s wort
22
Cytochrome P450 2D6
 Absent in 7% of Caucasians,
1–2% non-Caucasians
 Hyperactive in up to 30% of East Africans
 Catalyzes primary metabolism of:
 Codeine
 Many -blockers
 Many tricyclic antidepressants
 Inhibited by:
 Fluoxetine
 Haloperidol
 Paroxetine
 Quinidine
23
Cytochrome P450 2C9
 Absent in 1% Caucasians and
African-Americans
 Primary metabolism of:
 Most NSAIDs (including COX-2)
 S-warfarin (the active form)
 Phenytoin
 Inhibited by:
 Fluconazole
24
Cytochrome P450 2C19
• Absent in 20–30% of Asians,
3–5% Caucasians
• Primary metabolism of:
– Diazepam
– Phenytoin
– Omeprazole
• Inhibited by:
– Omeprazole
– Isoniazid
– Ketoconazole
25
Cytochrome P450 1A2
• Induced by smoking tobacco
• Catalyzes primary metabolism of:
– Theophylline
– Imipramine
– Propranolol
– Clozapine
• Inhibited by:
– Many fluoroquinolone antibiotics
– Fluvoxamine
– Cimetidine
26
27
Interactions Affecting Renal Excretion
 The pharmacokinetic properties of drugs that are
primarily renally excreted may be altered by changes
to active transport systems, urinary pH, and renal
blood flow.
 The acidic compounds phenobarbital, aspirin, and
other salicylates, with concurrent antacid or sodium
bicarbonate administration
 Probenecid use with penicillin or cephalosporins
 Methotrexate with NSAIDs.
 Lithium with NSAIDs
The end!!
28

Drug interactions

Uploaded by

Copyright:

Available Formats

Drug interactions

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Drug interactions

Uploaded by

Copyright:

Available Formats

Introduction to Pharmacotherapy:

• The frequency and significance of drug interactions

• Drug interactions are regarded as clinically

• Geriatric patients, polypharmacy and taking drugs

• The clinical severity of the effect of interaction can be

 Moderate interactions often require an alteration in

 Severe interactions should generally be avoided

 A change in the extent of drug absorption that

 The extent of absorption can be affected by

 Change in gastrointestinal PH (ketoconazole and H2

 Change in gastrointestinal motility (Metoclopramide

 Theoretically, drugs that are highly protein bound

 In general, due to a compensatory increase in

 drug metabolism is composed of 2 distinct pathways

 Modulation of CYP-mediated metabolism is the

 Most clinically significant metabolic interactions

 Enzyme inhibition occurs when the inhibitor drug

You might also like